Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Dosing Schedules in Combination With Darolutamide + ADT in mHSPC
NCT05676203Phase 3Active, not recruiting
- Sponsor
- Universitätsklinikum Jena
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of docetaxel in prostate cancer (PCa), sponsored by Universitätsklinikum Jena. Started May 2023; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05676203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676203.